drugset / Trial / NCT00807222

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00807222

RandomizedParallel-groupTriple-blindTreatment

Summary

This study involves research to test how Vyvanse (study drug) affects sleep in 24 children aged 6 to 12 years who have ADHD. Vyvanse is approved by the FDA for the treatment ADHD of in children aged 6 to 12 years. The experimental part of this study is to determine how Vyvanse affects sleep.

Timeline

Start
2008-04
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lisdexamfetamine Other / unclassified 30 mg Oral
Comparator Lisdexamfetamine Other / unclassified 50 mg Oral
Comparator Lisdexamfetamine Other / unclassified 70 mg Oral